Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants.

Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants.

In recent years, new direct-acting antivirals for hepatitis C virus (HCV) have been approved, but hepatitis C continues to pose a threat to human health. It is important to develop neutralizing anti-HCV antibodies to prevent medical and accidental infection, such as might occur via liver transplanta...

Full description

Bibliographic Details
Main Authors: Hiroshi Yokokawa, Midori Shinohara, Yuji Teraoka, Michio Imamura, Noriko Nakamura, Noriyuki Watanabe, Tomoko Date, Hideki Aizaki, Tomokatsu Iwamura, Hideki Narumi, Kazuaki Chayama, Takaji Wakita
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2022-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0274283

Internet

https://doi.org/10.1371/journal.pone.0274283

Similar Items